Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing.
Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing.
Cidara Therapeutics宣佈將Rezafungin剝離給Mundipharma，重新收購了 CD388 的全球開發和商業權，並宣佈了2.4億美元的私募融資，此後，該公司股價走高。
Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing.
Cidara Therapeutics宣佈將Rezafungin剝離給Mundipharma，重新收購了 CD388 的全球開發和商業權，並宣佈了2.4億美元的私募融資，此後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。